RJA
LABP

Raymond James & Associates’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Raymond James & Associates’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,035
Closed -$8K – 4174
2022
Q2 		$8K Buy
+1,035
New +$9.41K ﹤0.01% 3953

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return

Raymond James & Associates's LABP Position: Q3 2022 in Review

Raymond James & Associates sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q3 2022, closing a stake of 1,035 shares — an estimated $8K sold.

Raymond James & Associates first reported a position in LABP in Q2 2022 and held it in 1 quarter. The position peaked at $8K in Q2 2022. 31 funds tracked by Wall St. Rank hold LABP as of Q3 2022.

  • Raymond James & Associates reported no remaining Landos Biopharma, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Raymond James & Associates sold 1,035 Landos Biopharma, Inc. Common Stock shares in Q3 2022, an estimated $8K.
  • Raymond James & Associates first reported a position in Landos Biopharma, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Raymond James & Associates's Landos Biopharma, Inc. Common Stock position peaked at $8K in Q2 2022.
  • 31 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.